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Objectives: The impact of economic evaluation studies on
health-care decision makers has been shown to be rather
limited. However, there is an increasing requirement 
for the cost-effectiveness of health-care interventions to
be considered in formulating and implementing guidelines
for clinical practice. This paper reports the ﬁndings of
recent focus group research among UK health authorities,
which examined the usefulness of published economic
evaluations within the decision-making processes. The
ﬁndings are presented and discussed in light of other
studies that have addressed this issue.
Methods: Focus group research was conducted with deci-
sion makers from a sample of two UK health authorities
using the National Health Service Economic Evaluation
Database (NHS EED) as a research vehicle to locate and
report the ﬁndings of relevant economic studies. The
study sample was initially invited to respond to ques-
tionnaires exploring the usefulness of published economic
evaluations in the decision-making process and to outline
particular topics that it felt would beneﬁt from similar
economic evidence. Following this, a detailed search was
undertaken to retrieve structured NHS EED abstracts on
these topics such that the usefulness and limitations of
economic evaluations to decision making could be deter-
mined.
Results: Decision makers generally recognized the useful-
ness and necessity of published economic evaluations in
informing their decision-making processes. However, 
the value of studies was often limited because of the 
poor generalizability of results, the narrowness of
research questions, and the lack of methodological rigor
common to many published studies. A total of 237 NHS
EED full abstracts were retrieved in the speciﬁed areas of
interest, which, within speciﬁed caveats, were generally
found to be useful as decision-making tools. There was a
general consensus among decision makers in favor of
developing a quality-scoring system for studies, thereby
going beyond the critical summaries given in NHS EED.
Conclusions: Decision makers value information on cost-
effectiveness as well as effectiveness alone, but meth-
odological improvements are necessary to increase the
reliability of economic studies. A quality-scoring system
for published studies would be a useful development as a
ﬁltering mechanism for decision makers but would raise
a number of challenges for health economists.
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Address correspondence to: Michael F. Drummond, 
Director, Centre for Health Economics, University of York, 
Heslington, York YO10 5 DD, UK. 
E-mail: chedir@york.ac.uk
This paper is based on a presentation given at the Third ISPOR
European Conference, Antwerp, November 2000.
The NHS EED Project is funded by the NHS R & D Program.
Christiane Hoffmann is a PhD candidate at the University of
Hannover, Germany.
Volume 5 • Number 2 • 2002
V A L U E  I N  H E A L T H
Do Health-Care Decision Makers Find Economic Evaluations
Useful? The Findings of Focus Group Research in 
UK Health Authorities
Christiane Hoffmann, MBA,1 Boyka A. Stoykova, MD, MSc,2 John Nixon, BA, Cert. Ed, MSc,2
Julie M. Glanville, BA, PGDip Lib, MSc,2 Kate Misso, BSc, PGDip,2
Michael F. Drummond, Professor, BSc, MCom, DPhil1
1Centre for Health Economics, University of York, United Kingdom; 2NHS Centre for Reviews and Dissemination University of York,
United Kingdom
ABSTRACT
Introduction
Although previous investigations have shown that
economic evaluation studies of health-care inter-
ventions are of limited use, decision makers gener-
ally recognize that economic considerations must be
taken into account when making decisions about
health-care resource allocation [1,2].
The recent move to include cost-effectiveness
ﬁndings in reviews commissioned by national regu-
latory bodies such as the newly formed National
Institute for Clinical Excellence (NICE) in the
United Kingdom not only acknowledges the impor-
tance of economic evaluations at the national policy
level but also raises the question of how economic
evaluations are to be integrated into healthcare
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decision making, both at the local level and within
the formulation of guidelines.
Despite this increasing awareness of the need for
economic evaluations, it is also generally accepted
that the quality of published studies is variable.
Moreover, researchers adopt a wide range of me-
thodological approaches that may not be familiar
to those making decisions about competing health
technologies. The interpretation of economic
studies may also be limited by the reader’s knowl-
edge of what constitutes good research in health
economics, and as such, the relative strengths and
weaknesses of particular studies may not be imme-
diately obvious.
Several surveys concerning the use of economic
evaluation by decision makers in the UK Nation-
al Health Service (NHS) have been conducted.
Drummond et al. [3] surveyed almost 800 individ-
uals (283 prescribing advisers, 400 directors of
pharmacy, 101 directors of public health) in the
United Kingdom by mail questionnaire. The fol-
lowing areas were considered: 1) the decision
makers’ knowledge of economics; 2) the importance
of efﬁciency as a decision-making criterion; 3)
sources of information on costs and outcomes used
by decision makers; 4) barriers to the use of eco-
nomic evaluation; and 5) actual application of the
results of economic evaluations. The authors con-
cluded that the use of economic evaluation at the
local level was not extensive. The main obstacles to
the use of study results related either to the inﬂexi-
bility of budgets, which limited the movement of
resources from secondary to primary care, or the
inability to free resources to adopt new therapies.
In addition there were concerns about the studies
themselves, such as the large number of assump-
tions and the credibility of industry-funded studies.
In another survey by Duthie et al. [4], 17 pairs
of UK NHS decision makers (a mixture of managers
and clinicians) were interviewed about the use-
fulness of economic studies and presented with a
variety of health-economics outcomes statements in
order to determine the relevance and appeal of
diverse health economic measures to different deci-
sion makers. The principal ﬁnding of this study was
that a high proportion of statements conveying 
traditional health-economics outcomes, including
incremental cost-effectiveness ratios, quality-
adjusted life years (QALYs) and willingness to pay,
were either not understood or were considered irrel-
evant by those surveyed.
A third survey by Crump et al. [5] involved 12
medical decision makers from the Leicestershire
Health Authority in the United Kingdom (four
medical directors of hospitals and eight local
general practitioners) who were interviewed indi-
vidually and also participated in a focus group dis-
cussion. The interviewees were ﬁrst asked what
information they would require to make decisions
regarding the use of a hypothetical new drug for
obesity, and were then asked more general questions
about their use of economic information, the 
relevance of economic considerations to particular
types of decisions, and barriers and incentives to 
the use of economic evidence. This was part of 
the European Network on Methodology and Ap-
plication of Economic Evaluation Techniques
(EUROMET) project [6], which investigated the
impact of health-economic studies on decision
making in nine European countries and sur-
veyed 1022 decision makers by postal question-
naire, semi-structured interviews, or through focus
groups.
The results of this study [5] largely conﬁrmed the
ﬁndings of the earlier work by Drummond et al. [3].
However, when asked which factors might encour-
age decision makers to make more use of econo-
mic evaluations, the interviewees placed particular
emphasis on the appraisal of studies by a trusted
source, the need for more ﬂexibility in health-care
budgets and more detailed explanations of the prac-
tical relevance of study results.
Whereas surveys of the kind carried out in the
United Kingdom and other European countries
have well-known limitations, these ﬁndings are
comparable with the results of similar studies
carried out in the United States. Several surveys
have been conducted to explore how managed care
organizations and hospitals establish formulary
policies and the relevance of cost-effectiveness
analyses to this process [7–9]. Despite increasing
awareness and use of economic evaluations, cost-
effectiveness information was found to be of 
secondary concern. US decision makers were also
found to lack expertise in health economics and
tended to prefer timely information targeted at the
decisions they had to make.
Whereas some of the concerns of decision
makers, such as those about rigidities in healthcare
budgets, could only be met by changes in the man-
agement and organization of healthcare systems,
others could be alleviated by changes in the ways
economic evaluation studies are accessed and pre-
sented. In particular, it would be possible to provide
busy decision makers with critical reviews of pub-
lished studies in a readily accessible form.
Several databases of economic evaluations now
exist. For example, the Collège des Economistes de
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la Santé (CODECS) Database, the NHS Economic
Evaluation Database (NHS EED), and the ofﬁce
and the Ofﬁce of Health Economics Health Eco-
nomic Evaluation Database (HEED) contain struc-
tured abstracts of published studies. In principle,
these should help overcome some of the barriers to
the use of economic evaluations identiﬁed by deci-
sion makers and can assist in assessing the useful-
ness and limitations of economic evaluations within
the decision-making process at the local level.
As a vehicle for this research we chose the NHS
EED [10] because in addition to being familiar 
with this particular database, we deemed it the 
most suitable for the task given that one of its stated
aims is to be a decision-making tool for the NHS.
To this end, and in contrast to certain other data-
bases, it provides critical assessments of published
studies and comments on their usefulness to the
NHS.
Objectives
The overall aim of this study is to explore whether
economic evaluations are widely used by health-
care professionals working in the UK NHS and
whether greater access to results of economic eval-
uations would be beneﬁcial. The detailed study
objectives are:
1. to determine current awareness of economic
studies and their use in the health care decision-
making process;
2. to identify topics of concern to decision makers
that may potentially beneﬁt from economic 
evidence;
3. to retrieve structured NHS EED abstracts 
dealing with topics identiﬁed in (2) and to
determine their usefulness to decision makers;
and
4. to identify, through discussion with decision
makers, recommendations for improving the
usefulness, quality, and reporting of economic
evaluations in the future.
Questionnaires addressing these issues were
developed and sent to participants prior to each
stage of the study as outlined in the following
section.
Methods
The study was facilitated as a result of the cooper-
ation of a convenience sample of decision makers
working for two different UK health authorities.
The two particular health authorities (Leicestershire
and North Yorkshire) were chosen because they had
demonstrated an interest in economic evaluation
and were interested in participating in the study.
Therefore, the results obtained are likely to repre-
sent a “best case” scenario regarding the usefulness
of economic evaluations. We return to this point in
the discussion.
Initially, letters of invitation outlining the objec-
tives and potential usefulness of the research were
sent to a senior ofﬁcial at each of the two health
authorities. Consent to conduct the study was ob-
tained and a number of health-care professionals
from each authority were subsequently identiﬁed to
participate in the study.
Because the survey approach common to some
of the previous studies has a number of limitations
with respect to the reliability of data collection and
possible gaps in participants’ knowledge, a focus
group method was adopted [11]. This qualitative
method offers the advantage of allowing researchers
to obtain in-depth comments and feedback from
participants in a more proactive, semi-structured
and interactive manner. The advantages associated
with the focus group [12] approach are:
• It stresses information exchange and the spon-
taneous and open manifestation of the respon-
dents’ knowledge, beliefs, and values.
• It is based on small groups (generally between 5
and 10 members) and tape recorded discussions.
• The discussions are led by an experienced mod-
erator assisted by a rapporteur who documents
the sessions’ main conclusions.
• Individuals are selected according to particular
professional categories.
• Participants are told to reproduce their basic
ideas, wishes and perceptions about a speciﬁc
issue or social reality.
• Discussions are transcribed and ordered system-
atically such that the results can be analyzed and
grouped into the main relevant categories.
This approach was particularly useful because
ultimately decision makers were invited to engage
in a process of assessment and feedback regard-
ing the methodology involved in conducting and
reporting economic evaluations. In practice, this
could only have been achieved effectively if face-to-
face meetings with both researchers and members
of the study sample had been conducted. This 
was especially pertinent to the explanation of the
methodology for economic evaluations and the
layout and rationale of the structured abstracts,
which were also used in the later stages of the
research.
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The health-care professionals making up the
sample of decision makers were closely associ-
ated with day-to-day decision-making processes
affecting the delivery and implementation of
medical services in their area of responsibility. The
Leicestershire sample consisted of eight individuals
responsible for emergency care and mental health.
Emergency care was represented by one consultant
in public-health medicine, two commissioning man-
agers, one specialist registrar in public-health med-
icine, one professor of orthopedic trauma surgery,
one associate clinical director in medicine, and 
one access service manager from a social services
department in Leicestershire. The project director
and director of ﬁnance for mental health were also
present.
Four participants from the North Yorkshire
health authority with the following backgrounds
took part: one professor and assistant director 
of clinical effectiveness; one consultant in public-
health medicine; one evidence-based quality devel-
opment manager; and one general practitioner
responsible for clinical governance for primary care
groups (PCGs).
The research was conducted over the course of
four meetings, two at each authority, and was coor-
dinated by two health economists from each group
with the appointed chairperson from each health
authority ensuring that all people had an opportu-
nity to participate. By ensuring that health au-
thorities chaired the meetings, the effects of the
researchers’ bias on the outcomes of the study 
were minimized. The meetings took place between
February and April 2000, with a period of approx-
imately 1 month between each pair of meetings.
To enable subsequent assessment of retrieved
study abstracts, the ﬁrst meeting included a brief
description of NHS EED in general terms and a
description of the reporting of economic evalua-
tions within that database. Participants were asked
to discuss their responses to the ﬁrst questionnaire,
which they had received beforehand. The question-
naire inquired about participants’ current use of
economic evaluations and asked them to suggest a
list of topics related to current or recent decisions
in their health authority that economic evaluations
could usefully inform.
Following the ﬁrst meeting, a systematic search
of the NHS EED was undertaken using keywords
describing the intervention, illness or patient group
of interest in addition to Medical Subject Headings
(MeSH) and other keywords relevant to the topic
of interest. Because the nature of this search was
extensive and related to all areas that members of
the focus groups had identiﬁed, it was not feasible
to report every subsearch in detail.
Copies of the retrieved abstracts, as well as
details of cost, reviews and methodology papers
found, were sent to the participants at each health
authority along with a second questionnaire that
dealt with the usefulness of the economic evidence
and the readability of the abstracts. At the second
meeting, the NHS EED research teams presented
the results of the searches and explained how they
were conducted to provide clariﬁcation on how
members of the group could retrieve economic evi-
dence in an area they could be involved with in the
future.
A ﬁnal consolidated version of the results was
forwarded to both health authorities prior to pub-
lication to limit the potential for adverse inﬂuences
and biases that could have been introduced by the
researchers.
Results
Overall, all participants considered the economic
evaluations and the results of the ﬁrst pair of meet-
ings to be useful in helping to inform health-care
decision making. The general consensus was that
economic considerations are essential to support the
decisions taken by managers and clinicians respon-
sible for ensuring that the health services provided
offer good value for money.
Most of the participants had previously used
published economic evaluations, although to vary-
ing degrees. In both groups it was emphasized that
some decisions cannot be based purely on economic
considerations because other quality issues, such as
the psychological well-being of the patient, or
equity considerations, may override economic
factors. Despite this caveat, all these issues should
in fact be taken into account in a comprehensive
economic evaluation. Representatives from both
health authorities expressed concerns regarding the
lack of generalizability of economic evaluations. In
general, it was thought that economic evaluation
studies were focused on very narrow and speciﬁc
questions that did not allow for the complexity of
decision-making processes in the real world, where
issues were much broader. Thus, as most pub-
lished health-economic studies explore the cost-
effectiveness of particular health technologies rather
than more general health programs, they were
viewed as being of limited use to decision makers
employed by health authorities.
Twenty speciﬁc areas that could beneﬁt from eco-
nomic evidence to support decision making were
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identiﬁed. These were used to conduct a systematic
search of the NHS EED, the details of which are
presented in Table 1. 
Initially, decision makers reacted positively to 
the pertinence of NHS EED abstracts summarizing
the ﬁndings of retrieved studies. In general, they
considered the abstracts to be a useful source of
information that could contribute to the decision-
making process and to the identiﬁcation of related
research.
A total of 164 abstracts were retrieved for the
Leicestershire Health Authority, of which 109 were
studies in emergency care and 55 were studies in the
area of mental health. A total of 73 full abstracts
were found for the North Yorkshire Health Author-
ity. Overall, 237 abstracts were retrieved through
the search of the NHS EED. Details pertaining 
to each clinical area identiﬁed are summarized in
Table 1.
That the retrieved abstracts contained informa-
tion that could be helpful to varying degrees was
highlighted during the discussion. A comment from
one of the participants from the Leicestershire
Health Authority indicated that one abstract on
assertive community treatment (ACT) was highly
relevant and proved to be useful for decisions
regarding the future implementation of ACT for
those with severe mental illnesses in Leicestershire.
Although a broad range of studies were retrieved,
not all of them were regarded as being useful in the
decision-making process. Participants did empha-
size that these were nonetheless helpful in identify-
ing areas in which economic evaluations remain 
to be conducted and in bringing other studies of
potential interest to their attention. Some abstracts
allowed decision makers to identify areas in which
they lacked speciﬁc knowledge, such as the sta-
tistical and methodological aspects of economic
evaluation.
Participants also identiﬁed certain factors that
could limit the use of economic evaluations re-
ported in NHS EED abstracts to support health-
care decision making. First, decision makers
underlined problems in generalizing the results of
health-economic studies to the UK setting given that
a high percentage of the studies were carried out
abroad, particularly in the United States. In fact,
65% of the economic evaluations on the NHS EED
are derived from studies conducted in the United
States [13]. Decision makers questioned the trans-
ferability of these ﬁndings to the UK NHS model
for delivery of health care.
Second, in some cases participants questioned 
the quality of the clinical evidence used in economic
evaluations. They were of the general view that 
critical (NHS EED) study summaries in some cases
were too brief and that it would be unwise to base
decisions on such ﬂawed papers. Third, they 
re-emphasized their view, expressed at the ﬁrst
meeting, that some economic evaluation studies
deal with very speciﬁc diseases or interventions and
consequently they cannot reﬂect the more complex
real-world conditions under which decision makers
have to act.
In particular, health authority representatives
found the abstracts supplied to be satisfactory in
terms of readability. Consistent with the ﬁndings of
similar studies, some of the participants experienced
problems with the economic terminology used. A
recurring suggestion was that the commentary and
conclusions should be at the beginning of structured
abstracts so that the principal ﬁndings and limita-
tions of the study would be evident at ﬁrst glance.
Regarding the doubts surrounding the quality of
clinical evidence, it was also suggested that NHS
EED abstracts should be more explicit in criticizing,
where appropriate, the original paper. Decision
makers also thought that details about the study
interventions were often too brief. They pointed out
that these details provide important background
Table 1 Clinical areas identiﬁed and search results
No. of 
NHS EED 
Area abstracts
1. Telemedicine 6
2. Acute/emergency admission 1
3. Nurse practitioners vs. doctors in minor injuries 
units 8
4. Ambulance/ﬁrst responders/paramedics/skill levels 14
5. Trauma assessment—home vs. hospital 24
6. Trauma/home 4
7. Chest pain and chest pain clinics 19
8. DVT—home vs. hospital care 22
9. DVTs (home) 6
10. Home hospital 5
11. Mental health—long-term side effects of treatment 41
12. Mental health—self-harm 1
13. Mental health—compliance with treatment 10
14. Mental health—ACT 2
15. Use of statins in the primary prevention of 
ischaemic heart disease 11
16. Management of back pain and the use of 
acupuncture 0
17. Hip replacement revision—before or after the 
symptomatic phase 6
18. Management of COPD 12
19. Stents and angioplasty and how they relate to 
CABG 12
20. Hip and knee replacement 32
TOTAL 237
Abbreviations:ACT, assertive outreach/assertive community treatment; CABG,
coronary artery bypass graft; COPD, chronic obstructive pulmonary disease;
DVT, deep vein thrombosis.
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information, which should be described more thor-
oughly. Participants also provided recommen-
dations as to how to improve the layout, such as
clearer headings and a more distinct separation of
sections. Furthermore, they favored a more interac-
tive interface offering links to relevant sites, i.e., to
glossaries and sources of health-economic informa-
tion such as the effectiveness bulletins provided to
the NHS Centre for Reviews and Dissemination.
Another useful improvement would be to provide a
ﬁlter for searching that would be based on varying
levels of evidence and could also limit a search to
speciﬁc years. This could eventually include some
form of quality-scoring system that would classify
studies according to different levels of quality of 
evidence.
The results with supporting quotations from par-
ticipants are summarized below in Table 2.
Discussion
In general, participants from both health authori-
ties had common views about the importance of
economic information in health-care policy and the
value of structured abstracts such as those provided
by the NHS EED, which they considered to 
be a useful source of input for decision making.
However, in only a few instances did an individual
economic evaluation answer a speciﬁc question.
This study identiﬁes a number of options that
could improve the usefulness of the NHS EED, and
other similar sources of economic evidence as tools
for decision makers. First, in view of the prepon-
derance of studies from abroad and their limited
generalizability to the UK NHS, more studies
applicable to NHS settings should be undertaken
and identiﬁed as a priority in literature searches of
databases like the NHS EED. This would ensure
that more reliable and meaningful results would be
available for health-policy decision making in the
United Kingdom.
Second, the main limitations identiﬁed by partic-
ipants were that published studies often tackled
narrow questions whereas decision makers had 
to deal with much broader issues. This criticism
demonstrates that the type of economic evaluation
undertaken may also be a factor in terms of a
study’s value to decision makers depending on 
the level at which it is being considered: clini-
cian-patient, health authority, or policymaker. 
For example, at the clinician-patient level, cost-
consequence studies—a subclassiﬁcation of cost-
effectiveness analyses—may be desirable because
they leave the health outcomes disaggregated and
explicit to the decision maker, with associated
resources and total costs being reported for each.
However, in making decisions that affect competing
health interventions across a wide range of clinical
Table 2 Principal ﬁndings from the current focus group research
Topic/area Positive points Negative points
Economic evaluations in • Most participants had used economic studies • Economic issues alone should not drive decisions.The
decision making to varying degrees quality of care provided must be taken into
• Useful in informing the decision making process consideration
• Economic considerations are essential if value • Not all studies retrieved were useful
for money is to be achieved
Methodology of economic • Generalizability of studies—Are studies from the US
evaluations applicable to a UK context?
• Focus on narrow questions—Decision makers face
broader areas such as how to manage speciﬁc patient
populations
• Because of narrow focus, many economic evaluations
are of limited value at the HA level
• Need for a quality scoring systems for studies.This can
act as a “ﬁlter” and identify high/low quality studies
• Poor quality of effectiveness evidence used in economic
evaluations
NHS EED abstracts • Useful source of information (to varying • Should be more overtly critical of poor quality studies
degrees) within the decision-making process • Need to clarify/explain use of terminology or jargon
• Can help in identifying other studies or areas • Call for commentary to be “at the beginning” of the
of interest abstracts
• Satisfactory in terms of readability • Descriptions of interventions are too brief
• Can help in identifying the need for future • Layout needs improving
research • More interactive interface with links to deﬁnitions/
• Reveal decision makers’ lack of knowledge of glossaries relating to health economics
health economics • Need for search ﬁlters that would more accurately
identify suitable studies
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specialties, a cost-utility approach such as cost per
quality-adjusted life year (QALY) may be preferable
because a common and aggregated beneﬁt mea-
sure is utilized, thereby making such comparisons
possible.
Third, the ﬁndings also suggest that decision
makers’ knowledge of underlying health-economic
concepts and methodology is often limited. This
problem might be overcome by the provision of
health-economics support within health authorities
which, at present, is only moderate or nonexistent.
Consequently, decision makers often feel insecure
about interpreting economic results and suggested
implementing a quality score or an overall assess-
ment in addition to structured abstracts. This would
provide immediate information about the quality
and validity of health-economic study ﬁndings and
could also be used as a ﬁlter when searching data-
bases offering structured and critical summaries,
such as the NHS EED. By grading health-economic
evaluations in this manner, studies of poor quality
could be eliminated a priori such that decision
makers could focus on relevant studies, which may
compensate for limited knowledge and may save
time and effort in identifying valid health-economic
evaluations.
However, if health economists did recognize 
the merit of developing an overall quality score, 
a number of challenges would have to be met. It
would be possible to start with one of the existing
methodological checklists and to assess the propor-
tion of items that had been handled satisfactorily 
in a given study. This approach was adopted by 
Jefferson et al. [14] in their assessment of the impact
of the BMJ guidelines for economic submissions on
the quality of studies submitted to the BMJ and The
Lancet. However, this approach assumes that the
criteria included in methodological checklists are: 
1) comprehensive; 2) mutually exclusive; and 3) 
of equal weight. These conditions are unlikely to 
hold, and considerable work and thought are still
required before a reliable quality score is available.
A recent study by Nixon and Pang [15] tackled
some of these issues in developing a percentage
score for economic evaluations originating in Japan.
Fourth, a potential limitation of economic eval-
uations highlighted by decision makers was lack 
of generalizability of results coming from other
countries and health-care systems. Much has been
written about the problems of generalizing from a
given economic evaluation, and various solutions
have been proposed [16]. Beyond the rather obvious
points of being transparent in one’s analysis and
reporting quantities of resources separately from
prices (unit costs), general guidance is difﬁcult to
give. More research is required to explore ways in
which particular study features limit their general-
izability and how it can be increased. The develop-
ment of interactive models to supplement published
studies may help, but some analysts have concerns
about this. In this respect, however, it is worth
emphasizing that the majority of studies abstracted
and recorded on the NHS EED and some other
databases are derived from US settings. Although
this may be considered a limitation for UK decision
makers, it may in fact be an advantage for US users
of these databases.
In terms of the methodological limitations of the
present study, it is possible that a degree of selec-
tion bias exists due to the use of a convenience
sample made up of health authorities constituted of
those willing to work co-operatively with the orga-
nizations undertaking the research. Certainly these
respondents are much more favorably disposed to
economic evaluation than the average. However, to
counter this argument, it could also be said that 
our results are better informed than those derived
from a random sample of health authorities because
the convenience sample was eager to pursue issues
related to improving evidence-based decision
making in the NHS. A number of steps were taken
to minimize the inﬂuence of sponsor bias by ensur-
ing that the meetings were under the control of each
health authority and by using NHS EED as a vehicle
rather than the principal focus of the research. Con-
sequently, there are no conﬂicts of interest, given
that funding or support for NHS EED is not directly
dependent on the outcome of the present study.
However, we acknowledge that similar research
using a larger, random sample of decision makers
would help to validate and extend the present 
ﬁndings.
Conclusions
Although NHS decision makers feel that economic
evaluations are useful in principle, in practice their
usefulness may be limited. Starting from topics gen-
erated by the decision makers themselves, we found
that although studies relating to the topics existed,
only in a few instances did published economic 
evaluations provide direct answers to the decision
makers’ questions. In particular, decision makers
were concerned that the results of published studies
may not apply to their settings. Rather, in most
instances published studies had more general uses
in helping decision makers structure the problem or
illuminate related topics.
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Structured databases like the NHS EED do fulﬁll
a useful function in that they help potential users
quickly identify relevant studies and provide com-
ments on their quality and relevance. However,
some of the respondents said they would like to 
see more details in the structured abstracts and
some reformatting, and that an overall quality score
might help them to focus on the most important
studies.
Many NHS decision makers are still unfamiliar
with economic terminology, and it would be useful
to launch training courses to educate them in the
basics of economic evaluation methodology and
searches of structured databases like the NHS EED.
Finally, it would be useful to conduct additional
studies of this type, perhaps using a larger random
sample of health authorities, to test some of the
hypotheses generated in this study.
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